logo
Plus   Neg
Share
Email

Canopy Growth Q3 Results Top View

Canopy Growth Corp. (CGC, WEED.TO) reported that its third-quarter net loss attributable to the company was C$120.97 million, compared to net income of C$67.58 million in the prior year.

Net loss per share narrowed to C$0.35 from C$0.38 last year. Analysts polled by Thomson Reuters expected the company to report a loss of C$0.49 per share. Analysts' estimates typically exclude special items.

Net revenue for the quarter grew to C$123.76 million from C$83.05 million in the prior year. Analysts expected revenues of C$105.1 million for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT
>